A multi-national biotechnology firm, Radikal Therapeutics (RTX) organizes around discovery and development of transformative pharmaceuticals anchored in a novel class of organic nitrate based nitric oxide donors. Principals of the firm approach their discovery work primarily utilizing classic rational-based medicinal chemistry approaches, supported by computational algorithms based upon crystallographic data. Rather than focusing on a particular therapeutic area, RTX personnel tackle biological problems of high fundamental interest common to disease pathogenesis, Experience suggests thet this approach produces novel chemistry that has broad applicability across disease states that share common underlying mechanisms of injury. The Company also operates an efficient in-house iterative drug discovery process: hits are subjected to rapid validation by in vitro cell culture testing with quick follow-on in vivo confirmation in rodent and large animal disease models. This approach consistently yields highly potent and innovative pharmaceutical candidates. Management note that in a previous firm, this strategy yielded multiple clinical candidates, one of which resulted in a major oncology partnership with large pharma and a second molecule that has advanced through late Phase 2 clinical trials with an impressive demonstration of clinical efficacy in the ophthalmic space.
